Magi María S, de Lafuente Yanina, Quarta Eride, Palena María C, Ardiles Perla Del R, Páez Paulina L, Sonvico Fabio, Buttini Francesca, Jimenez-Kairuz Alvaro F
Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba (UNC), Córdoba X5000GYA, Argentina.
Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET-UNC), Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba X5000HUA, Argentina.
Pharmaceutics. 2024 Mar 22;16(4):436. doi: 10.3390/pharmaceutics16040436.
Polyelectrolyte-drug complexes are interesting alternatives to improve unfavorable drug properties. Vancomycin (VAN) is an antimicrobial used in the treatment of methicillin-resistant pulmonary infections in patients with cystic fibrosis. It is generally administered intravenously with a high incidence of adverse side effects, which could be reduced by intrapulmonary administration. Currently, there are no commercially available inhalable formulations containing VAN. Thus, the present work focuses on the preparation and characterization of an ionic complex between hyaluronic acid (HA) and VAN with potential use in inhalable formulations. A particulate-solid HA-VAN complex was obtained by spray drying from an aqueous dispersion. FTIR spectroscopy and thermal analysis confirmed the ionic interaction between HA and VAN, while an amorphous diffraction pattern was observed by X-ray. The powder density, geometric size and morphology showed the suitable aerosolization and aerodynamic performance of the powder, indicating its capability of reaching the deep lung. An in vitro extended-release profile of VAN from the complex was obtained, exceeding 24 h. Microbiological assays against methicillin-resistant and -sensitive reference strains of showed that VAN preserves its antibacterial efficacy. In conclusion, HA-VAN exhibited interesting properties for the development of inhalable formulations with potential efficacy and safety advantages over conventional treatment.
聚电解质 - 药物复合物是改善不良药物性质的有趣替代物。万古霉素(VAN)是一种用于治疗囊性纤维化患者耐甲氧西林肺部感染的抗菌药物。它通常通过静脉给药,副作用发生率高,而通过肺内给药可以降低副作用。目前,尚无含有万古霉素的市售可吸入制剂。因此,本研究重点关注透明质酸(HA)与万古霉素之间离子复合物的制备与表征,该复合物具有用于可吸入制剂的潜在用途。通过从水分散体中喷雾干燥获得了颗粒状固体HA - VAN复合物。傅里叶变换红外光谱(FTIR)和热分析证实了HA与VAN之间的离子相互作用,而X射线观察到无定形衍射图谱。粉末密度、几何尺寸和形态表明该粉末具有合适的雾化和空气动力学性能,表明其能够到达肺深部。获得了复合物中万古霉素的体外缓释曲线,超过24小时。针对耐甲氧西林和敏感参考菌株的微生物学试验表明,万古霉素保留了其抗菌效力。总之,HA - VAN在开发具有优于传统治疗的潜在疗效和安全性优势的可吸入制剂方面表现出有趣的特性。